摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1H-benzimidazol-2-yl(oxo)acetic acid

中文名称
——
中文别名
——
英文名称
1H-benzimidazol-2-yl(oxo)acetic acid
英文别名
2-(1H-benzimidazol-2-yl)-2-oxoacetic acid
1H-benzimidazol-2-yl(oxo)acetic acid化学式
CAS
——
化学式
C9H6N2O3
mdl
MFCD02666808
分子量
190.16
InChiKey
UKQJEQZOFFQAQL-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    1
  • 重原子数:
    14
  • 可旋转键数:
    2
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.0
  • 拓扑面积:
    83
  • 氢给体数:
    2
  • 氢受体数:
    4

文献信息

  • Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides
    申请人:——
    公开号:US20040063744A1
    公开(公告)日:2004-04-01
    This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4
    这项发明提供了具有药物和生物影响性能的化合物,它们的药物组合物和使用方法。具体而言,该发明涉及具有独特抗病毒活性的新哌啶4-烯基衍生物。更具体地说,本发明涉及用于治疗艾滋病毒和艾滋病的化合物。本发明的化合物为一般式I的化合物: 1 其中: Z是 2 Q是从以下组中选择的: 3 —W—是 4
  • Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
    申请人:——
    公开号:US20040266668A1
    公开(公告)日:2004-12-30
    The present invention relates to compounds of Formula I or II, or a pharmaceutically acceptable salt, ester, or prodrug, thereof: 1 which inhibit serine protease activity, particularly the activity of hepatitis C virus (HCV) NS3-NS4A protease. Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
    本发明涉及式I或II的化合物,或其药学上可接受的盐、酯或前药:1,其抑制丝氨酸蛋白酶活性,特别是乙型肝炎病毒(HCV)NS3-NS4A蛋白酶的活性。因此,本发明的化合物干扰乙型肝炎病毒的生命周期,并且也可用作抗病毒剂。本发明还涉及含有上述化合物的药物组合物,用于治疗患有HCV感染的受试者。该发明还涉及通过给受试者投予含有本发明化合物的药物组合物来治疗HCV感染的方法。
  • Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives
    申请人:——
    公开号:US20040006090A1
    公开(公告)日:2004-01-08
    This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with sulfonylureido piperazine derivatives of Formula I. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. 1 wherein: Z is 2 Q is selected from the group consisting of: 3 —W— is 4 —represents a carbon-carbon bond or does not exist; and A is NR 13 R 14 .
    该发明提供了具有药物和生物影响特性的化合物,它们的药物组合物及使用方法。具体而言,该发明涉及式I的磺酰哌嗪生物。这些化合物具有独特的抗病毒活性,无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂结合使用。更具体地,本发明涉及HIV和艾滋病的治疗。其中:Z是;Q是选择自组中的一种;—W—是;—代表碳-碳键或不存在;A是NR13R14。
  • Indole, azaindole and related heterocyclic N-substituted piperazine derivatives
    申请人:Yeung Kap-Sun
    公开号:US20050261296A1
    公开(公告)日:2005-11-24
    This invention provides compounds of Formula I, including pharmaceutically accceptable salts thereof, having drug and bio-affecting properties, their pharmaceutical compositions and method of use. These compounds possess unique antiviral activity, whether used alone or in combination with other antivirals, antiinfectives, immunomodulators or HIV entry inhibitors. More particularly, the present invention relates to the treatment of HIV and AIDS. The compounds of Formula I have the formula wherein: Z is Q is selected from the group consisting of m is 2; A is selected from the group consisting of cinnolinyl, napthyridinyl, quinoxalinyl, pyridinyl, pyrimidinyl, quinolinyl, isoquinolinyl, quinazolinyl, azabenzofuryl, and phthalazinyl each of which may be optionally substituted with one or two groups independently selected from methyl, methoxy, hydroxy, amino and halogen; and —W— is
    这项发明提供了具有药物和生物影响性质的Formula I化合物,包括其药用盐,以及它们的药物组合物和使用方法。这些化合物具有独特的抗病毒活性,无论是单独使用还是与其他抗病毒药物、抗感染药物、免疫调节剂或HIV进入抑制剂结合使用。更具体地,本发明涉及治疗HIV和艾滋病。Formula I化合物的结构如下:Z是Q是从以下组中选择的m为2;A是从以下组中选择的:啰啉基、啉基、喹喉基、吡啶基、嘧啶基、喹啉基、异喹啉基、喹唑啉基、氮杂苯并呋喃基和邻苯二嗪基,每种基可能被一个或两个分别选择自甲基、甲氧基、羟基、基和卤素的基取代;而—W—是。
  • INDOLE, AZAINDOLE AND RELATED HETEROCYCLIC 4-ALKENYL PIPERIDINE AMIDES
    申请人:Wang Tao
    公开号:US20080188481A1
    公开(公告)日:2008-08-07
    This invention provides compounds having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with new piperidine 4-alkenyl derivatives that possess unique antiviral activity. More particularly, the present invention relates to compounds useful for the treatment of HIV and AIDS. The compounds of the invention for the general Formula I: wherein: Z is Q is selected from the group consisting of: —W— is
    本发明提供了具有药物和生物影响性质的化合物,它们的制药组合物和使用方法。具体而言,本发明涉及具有独特的抗病毒活性的新的哌啶4-烯基衍生物。更具体地,本发明涉及用于治疗HIV和艾滋病的化合物。本发明的化合物一般公式为I:其中:Z是Q是从以下组中选择的:-W-是
查看更多